Promotions & Moves

Avacta Names Fiona McLaughlin as Therapeutics Division CSO

Dr. McLaughlin is a highly experienced oncology drug developer, bringing over 25 years of experience in research and translational drug development.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Avacta Group plc, a clinical stage biopharmaceutical company developing cancer therapies and diagnostics based on its Affimer® and pre|CISION™ platforms, has appointed Dr. Fiona McLaughlin as Chief Scientific Officer of its Therapeutics Division.   Dr. McLaughlin is a highly experienced oncology drug developer, bringing over 25 years of experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters